Demichelis, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 9.778
EU - Europa 1.580
AS - Asia 487
OC - Oceania 8
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 7
AF - Africa 1
Totale 11.869
Nazione #
US - Stati Uniti d'America 9.769
IT - Italia 357
SE - Svezia 296
UA - Ucraina 256
FI - Finlandia 217
GB - Regno Unito 206
CN - Cina 192
SG - Singapore 130
DE - Germania 104
VN - Vietnam 77
BG - Bulgaria 58
JO - Giordania 26
LU - Lussemburgo 22
IN - India 15
TR - Turchia 15
HK - Hong Kong 12
RU - Federazione Russa 10
CA - Canada 8
CZ - Repubblica Ceca 8
AT - Austria 7
AU - Australia 6
ES - Italia 5
IR - Iran 5
JP - Giappone 5
NL - Olanda 5
RO - Romania 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CL - Cile 4
FR - Francia 4
PL - Polonia 4
BR - Brasile 3
EU - Europa 3
KR - Corea 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
IL - Israele 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CH - Svizzera 1
CR - Costa Rica 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
IE - Irlanda 1
LK - Sri Lanka 1
MC - Monaco 1
ME - Montenegro 1
MK - Macedonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 11.869
Città #
Fairfield 1.720
Chandler 956
Ashburn 836
Woodbridge 790
Seattle 695
Houston 623
Jacksonville 610
Cambridge 586
Wilmington 558
San Mateo 334
Ann Arbor 326
Princeton 226
Beijing 120
Trento 118
San Diego 108
Helsinki 104
New York 89
Boardman 82
Dearborn 79
London 73
Lawrence 70
Singapore 69
Sofia 58
Como 56
Los Angeles 54
Dong Ket 50
Falls Church 40
Bremen 34
Norwalk 27
San Paolo di Civitate 27
Tolentino 23
Hesperange 22
Altamura 21
Des Moines 21
Bend 20
Dallas 20
Washington 17
Kilburn 16
Düsseldorf 15
Izmir 15
Andover 13
Hong Kong 12
Hefei 11
Bonndorf 10
Kunming 10
Chiswick 9
Phoenix 9
Acton 8
Bassano del Grappa 8
Nanjing 8
New Bedfont 8
Riva Del Garda 8
Rome 8
Toronto 8
Wandsworth 8
Brno 7
Vienna 7
Chicago 6
Civitanova Marche 6
Lappeenranta 6
Milan 6
Prescot 6
Bolzano 5
Dormagen 5
Pune 5
Tappahannock 5
Guangzhou 4
Hounslow 4
Laurel 4
Lavis 4
Mountain View 4
Munich 4
Redmond 4
Southwark 4
Vicenza 4
Zhengzhou 4
Bovolone 3
Fuzhou 3
Hebei 3
San Michele All'adige 3
Shanghai 3
Tokai 3
Turin 3
Anaheim 2
Asolo 2
Atlanta 2
Auckland 2
Augusta 2
Berlin 2
Brisbane 2
Bristol 2
Brunico 2
Castello Molina di Fiemme 2
Chapel Hill 2
Clearwater 2
Costa Mesa 2
Falkenstein 2
Forest City 2
Fremont 2
Geelong 2
Totale 10.005
Nome #
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit 249
Inherited determinants of early recurrent somatic mutations in prostate cancer 236
EthSEQ: ethnicity annotation from whole exome sequencing data 187
A highly specific SpCas9 variant is identified by in vivo screening in yeast 165
ASEQ: Fast allele-specific studies from next-generation sequencing data 147
Patient derived organoids to model rare prostate cancer phenotypes 143
Personalized in vitro and in vivo cancer models to guide precision medicine 142
Second Generation Imaging of Nuclear/Cytoplasmic HIV-1 Complexes. 139
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study 137
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood 132
Genomic correlates of clinical outcome in advanced prostate cancer 129
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer 123
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth 123
High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients 119
TPES: Tumor Purity Estimation from SNVs 114
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer 111
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. 108
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers 108
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer 107
Defining order and timing of mutations during cancer progression: The TO-DAG probabilistic graphical model 106
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer 106
RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer 105
Genomic correlates to the newly proposed grading prognostic groups for prostate cancer 103
The Molecular Taxonomy of Primary Prostate Cancer 101
In-silico identification and functional validation of allele-dependent AR enhancers 101
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. 99
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer 99
Variants at IRX4 as prostate cancer expression quantitative trait loci. 97
Analysis of user-satisfaction with the use of a teleconsultation system in oncology. 97
Testing mutual exclusivity of ETS rearranged prostate cancer. 97
PaCBAM: Fast and scalable processing of whole exome and targeted sequencing data 97
Ancestry-specific predisposing germline variants in cancer 97
Punctuated evolution of prostate cancer genomes. 96
An automated procedure to properly handle digital images in large scale tissue microarray experiments. 94
Role of non-coding sequence variants in cancer 94
A Comparative Study of ERG Status Assessment on DNA, mRNA, and Protein Levels Using Unique Samples from a Swedish Biopsy Cohort. 94
Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. 93
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. 93
An evaluation of the use of and user satisfaction with a teleconsultation system in oncology practice. 93
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. 92
Oncogene-mediated alterations in chromatin conformation 91
Clonal evolution of chemotherapy-resistant urothelial carcinoma 91
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. 90
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. 89
User attitudes in analyzing digital slides in a quality control test bed: a preliminary study. 89
Tumor clone dynamics in lethal prostate cancer 89
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care 89
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. 89
A step toward functionally characterized prostate cancer molecular subtypes. 88
Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. 88
Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. 88
The virtual case: a new method to completely digitize cytological and histological slides. 88
Plasma AR and abiraterone-resistant prostate cancer 88
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. 86
Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease 86
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 86
The genomic complexity of primary human prostate cancer. 86
Robotic telepathology for intraoperative remote diagnosis using a still-imaging-based system. 86
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations 86
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. 85
Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. 85
Integrative clinical genomics of advanced prostate cancer 85
TMABoost: an integrated system for comprehensive management of tissue microarray data. 84
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. 84
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer 84
Large oncosomes mediate intercellular transfer of functional microRNA. 83
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. 83
Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. 82
EML4-ALK fusion lung cancer: a rare acquired event. 82
Digital Pathology: Science Fiction? 82
Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression 82
Recurrent gene fusions in prostate cancer 81
Genetic predisposition to prostate cancer: Update and future perspectives 81
Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations 81
Design and initial implementation of a regional tele-oncology project. 80
ERG rearrangement metastasis patterns in locally advanced prostate cancer. 80
Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. 80
Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. 80
The landscape of somatic copy-number alteration across human cancers. 79
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 79
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. 79
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets 78
Antibody-based detection of ERG rearrangement-positive prostate cancer. 78
Digital storage of glass slides for quality assurance in histopathology and cytopathology. 78
Molecular genetics of prostate cancer: Emerging appreciation of genetic complexity 78
Unraveling the clonal hierarchy of somatic genomic aberrations 78
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation 77
The lethal clone in prostate cancer: redefining the index 77
A computational framework discovers new copy number variants with functional importance. 77
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk 77
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. 77
Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. 77
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. 77
Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. 75
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. 75
V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. 74
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. 74
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. 74
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer 74
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. 73
Totale 9.695
Categoria #
all - tutte 61.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 456
selected - selezionate 0
volume - volumi 229
Totale 62.629


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.603 0 0 211 305 316 203 339 280 432 249 108 160
2020/20212.590 40 357 159 330 265 182 151 162 161 230 282 271
2021/20222.157 249 327 14 92 36 81 83 390 137 212 181 355
2022/20232.024 267 235 13 328 210 316 30 145 252 34 122 72
2023/2024822 49 77 67 28 76 177 45 92 10 80 32 89
2024/202580 18 36 26 0 0 0 0 0 0 0 0 0
Totale 12.161